Piper Sandler lowered the firm’s price target on Xeris Biopharma to $3 from $4 and keeps an Overweight rating on the shares. The company’s Q1 results slightly missed expectations, the analyst tells investors. Looking beyond this year, the firm believes Xeris has a “clear line of sight” into sustainable cash generation and EBITDA growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma reports Q1 EPS (14c), consensus (12c)
- Xeris Biopharma enters collaboration, license agreement with Beta Bionics
- Xeris Biopharma enters exclusive license agreement with Beta Bionics
- Xeris Biopharma initiated with an Outperform at Oppenheimer
- Acelyrin price target raised to $13 from $11 at Wells Fargo
